US Patent

US11324751 — Dosing regimens associated with extended release paliperidone injectable formulations

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2041-05-07 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating patients with long-acting injectable paliperidone palmitate formulations.

USPTO Abstract

The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.

Drugs covered by this patent

Invega Sustenna (PALIPERIDONE PALMITATE) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3359`	—	Invega Sustenna
`U-3359`	—	Invega Sustenna

Patent Metadata

Patent number: US11324751
Jurisdiction: US
Classification: Method of Use
Expires: 2041-05-07
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.